The CGRD is the largest multi-institutional electronic medical record (EMR) database in Taiwan [21], including 2 medical centers and five general hospitals, and information on more than 11 million patients from 2001 to 2019
The buyer's institution assumes compliance responsibility for federal and provincial research regulations, and the vial does not carry Health Canada authorization for any human or veterinary indication
The research methodology used to estimate the market size includes the following: The list of approved GLP-1 agonists was identified through extensive secondary and primary research
In the Phase 2 clinical trial, obese patients treated with a 12-milligram dose for 48 weeks experienced an average weight reduction of 24.2% (approximately 58 pounds/26.2 kilograms), significantly better than the 2.1% reduction in the placebo group
Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al
Thymosin Alpha-1 peptide research solutions are frequently organized together with PT-141 peptide products within advanced scientific research environments
